Licensed vaccine
RabAvert
FDA-licensed vaccine · Bavarian Nordic A/S Indication: For pre-exposure vaccination, in both primary series and booster dose, and for post-exposure prophylaxis against rabies in all age groups. · STN BL 103334
Key facts
| Trade name | RabAvert |
|---|---|
| Proper name | Rabies Vaccine |
| Manufacturer | Bavarian Nordic A/S Indication: For pre-exposure vaccination, in both primary series and booster dose, and for post-exposure prophylaxis against rabies in all age groups. |
| Submission tracking number (STN) | BL 103334 |
| Recent FDA documents | October 30, 2024 Approval Letter - RabAvert, May 9, 2024 Approval Letter - RabAvert, October 3, 2023 Approval Letter - RabAvert, August 3, 2018 Approval Letter - RabAvert, Package Insert - RabAvert, Supporting Documents older than three years - RabAvert - Rabies Vaccine |
| FDA page updated | Oct 31, 2024 |
| FDA product page | fda.gov |
At a glance
- 1–9 FDA approval letters
- 1–9 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: